share_log

醫思健康:截至二零二四年九月三十日止六個月之中期業績公告

EC HEALTHCARE: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

HKEX ·  Nov 28 12:03

Summary by Futu AI

截至2024年9月30日止六個月,醫思健康錄得總收入2,062.9百萬港元,同比下降2.8%。儘管收入下降,淨溢利達40.3百萬港元,同比增長88.1%,每股盈利增至1.2港仙,派息1.0港仙。醫療服務收入下降3.7%至1,264.3百萬港元,而美學醫療及美容收入減少5.4%至629.8百萬港元。獸醫及其他服務收入則增長18.3%至168.9百萬港元。\\n管理層指出,淨溢利增長主要因新設立服務點的營運效率提高、總部租金及員工開支的成本優化,以及淨利息開支減少。公司將繼續專注於增強服務網絡的互聯互通,抓住B2B、B2I及B2G機會,並加強內部生態系統的協同效應。未來,公司計劃進一步提升營運效率...展開全部
截至2024年9月30日止六個月,醫思健康錄得總收入2,062.9百萬港元,同比下降2.8%。儘管收入下降,淨溢利達40.3百萬港元,同比增長88.1%,每股盈利增至1.2港仙,派息1.0港仙。醫療服務收入下降3.7%至1,264.3百萬港元,而美學醫療及美容收入減少5.4%至629.8百萬港元。獸醫及其他服務收入則增長18.3%至168.9百萬港元。\\n管理層指出,淨溢利增長主要因新設立服務點的營運效率提高、總部租金及員工開支的成本優化,以及淨利息開支減少。公司將繼續專注於增強服務網絡的互聯互通,抓住B2B、B2I及B2G機會,並加強內部生態系統的協同效應。未來,公司計劃進一步提升營運效率及財務業績,並審慎管理營運資金以確保資產負債表穩健。\\n展望未來,醫思健康將專注於業務發展、卓越營運及數字化轉型。公司將利用平台方法創造相關產品,並把握B2B、B2I及PPP增長機會。公司亦將優化資產組合,出售非核心資產,並重新分配資本至增長前景更美好的新投資,以確保長期發展及可持續增長。
As of the six months ended September 30, 2024, ec healthcare recorded total revenue of 2062.9 million Hong Kong dollars, a year-on-year decrease of 2.8%. Despite the decrease in revenue, net profit reached 40.3 million Hong Kong dollars, an 88.1% year-on-year increase, with earnings per share rising to 1.2 Hong Kong cents and a dividend of 1.0 Hong Kong cents. Medical service revenue decreased by 3.7% to 1264.3 million Hong Kong dollars, while aesthetic medical and beauty revenue decreased by 5.4% to 629.8 million Hong Kong dollars. Veterinary and other service revenue increased by 18.3% to 168.9 million Hong Kong dollars.Management pointed out that the growth in net profit was mainly due to the operational efficiency improvement of newly established service points, cost optimization of headquarters rent and staff...Show More
As of the six months ended September 30, 2024, ec healthcare recorded total revenue of 2062.9 million Hong Kong dollars, a year-on-year decrease of 2.8%. Despite the decrease in revenue, net profit reached 40.3 million Hong Kong dollars, an 88.1% year-on-year increase, with earnings per share rising to 1.2 Hong Kong cents and a dividend of 1.0 Hong Kong cents. Medical service revenue decreased by 3.7% to 1264.3 million Hong Kong dollars, while aesthetic medical and beauty revenue decreased by 5.4% to 629.8 million Hong Kong dollars. Veterinary and other service revenue increased by 18.3% to 168.9 million Hong Kong dollars.Management pointed out that the growth in net profit was mainly due to the operational efficiency improvement of newly established service points, cost optimization of headquarters rent and staff expenses, as well as a reduction in net interest expenses. The company will continue to focus on enhancing the interconnected service network, seizing B2B, B2I, and B2G opportunities, and strengthening the synergies within the internal ecosystem. In the future, the company plans to further enhance operational efficiency and financial performance, and prudently manage operational funds to ensure a robust balance sheet.Looking ahead, ec healthcare will focus on business development, operational excellence, and digital transformation. The company will use a platform approach to create related products, seize B2B, B2I, and PPP growth opportunities. The company will also optimize its asset portfolio, divest non-core assets, and reallocate capital to new investments with better growth prospects to ensure long-term development and sustainable growth.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.